Hypoxic Ischemic Encephalopathy Clinical Trial
Official title:
Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia
Hypoxic-Ischemic Encephalopathy (HIE) occurs in 20 per 1000 births. Only 47% of neonates treated with the state of the art therapy (induced systemic hypothermia) have normal outcomes. Therefore, other promising therapies that potentially work in synergy with hypothermia to improve neurologic outcomes need to be tested. One potential agent is melatonin. Melatonin is a naturally occurring substance produced mainly from the pineal gland. Melatonin is widely known for its role in regulating the circadian rhythm, but it has many other effects that may benefit infants with HI injury. Melatonin serves as a free radical scavenger, decreases inflammatory cytokines, and stimulates anti-oxidant enzymes. Therefore, melatonin may interrupt several key components in the pathophysiology of HIE, in turn minimizing cell death and improving outcomes. The research study will evaluate the neuroprotective properties and appropriate dose of Melatonin to give to infants undergoing therapeutic hypothermia for hypoxic ischemic encephalopathy.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | March 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 6 Hours |
Eligibility | Inclusion Criteria: - Eligible infants are >36 0/7th weeks gestation, - pH (cord or neonatal) <7.0, - base deficit >16 mEq/L, - no available blood gas, - a cord blood/first hour of life blood gas with pH > 7.0 and < 7.15, - base deficit between 10 and 15.9 mEq/L, - infants must have a history of an acute perinatal event, - either a 10-minute Apgar < 5 or a continued need for ventilation, - All infants must have signs of encephalopathy within 6 hours of age using the modified Sarnat scoring system, - neonates cooled within 6 hours of birth will be included in the study. Exclusion Criteria: - suspected inborn errors of metabolism (elevated ammonia) and hypoglycemia, - clinical signs and symptoms consistent with meningitis detected upon sepsis evaluation, - a diagnosis of congenital abdominal surgical problems along with multiple congenital anomalies and/or chromosomal abnormalities. |
Country | Name | City | State |
---|---|---|---|
United States | University of Florida | Gainesville | Florida |
United States | Florida Hospital for Children | Orlando | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida | Thrasher Research Fund |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To identify the maximum tolerated dose of Melatonin | The maximum tolerated dose (MTD) is defined as the highest dose level without adverse events in no more than 1 out of 6 patients | Changes in Baseline to day 3 | |
Primary | Bayley-III Index Scores (Cognitive, Language, and Motor) will be used for neurological outcome assessment | All raw scores will be transformed into norm-referenced standard scores (scale mean = 100 with s.d. = 15) using the Bayley-III scoring software published with the test. To dichotomize "good" and "poor" outcomes for statistical analysis, standardized scores that are at or greater than one standard deviation below the normative sample mean published with the test (i.e., standard scores < 85) will be classified as "poor outcome" while higher scores will be classified as "good outcome". | Approximately 18 - 20 Months | |
Primary | Peak Plasma Concentration (Cmax) of Melatonin 0.5 mg/kg. | HPLC-ESI/MS/MS will be used to measure melatonin concentrations in the serum samples. The two-way ANOVA (treatments are dose level and timepoint) framework for testing. Testing will be done using a likelihood ratio test, either using large-sample theory approximation or using bootstrap. | 0 (baseline), 3, 5, 6, 12, 24, 48, 96 hours and day 14 (one sample) | |
Primary | Number of participants with treatment-related adverse events as assessed by MedDRA ??? This is something the PI/Team needs to agree on which one to use. | Incidence/Grade of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), laboratory abnormalities Percentage and number of subjects who discontinued for adverse event | Baseline ongoing to Day 14 | |
Primary | Peak Plasma Concentration (Cmax) of Melatonin 3 mg/kg. | HPLC-ESI/MS/MS will be used to measure melatonin concentrations in the serum. The two-way ANOVA (treatments are dose level and timepoint) framework for testing. Testing will be done using a likelihood ratio test, either using large-sample theory approximation or using bootstrap. | 0 (baseline), 3, 5, 6, 12, 24, 48, 96 hours and day 14 (one sample) | |
Primary | Peak Plasma Concentration (Cmax) of Melatonin 5 mg/kg. | HPLC-ESI/MS/MS will be used to measure melatonin concentrations in the serum samples. The two-way ANOVA (treatments are dose level and timepoint) framework for testing. Testing will be done using a likelihood ratio test, either using large-sample theory approximation or using bootstrap. | 0 (baseline), 3, 5, 6, 12, 24, 48, 96 hours and day 14 (one sample) | |
Secondary | Bayley-III Index Scores Subscales (Receptive and Expressive Language, Fine and Gross Motor) will be used for neurological outcome assessment | The four performance-based subscales of the Bayley-III Index Scores (Receptive and Expressive Language, Fine and Gross Motor) and two parent-reported scales (Social-Emotional and Adaptive Behavior) will be collected. All raw scores will be transformed into norm-referenced standard scores (scale mean = 100 with s.d. = 15) using the Bayley-III scoring software published with the test. To dichotomize "good" and "poor" outcomes for statistical analysis, standardized scores that are at or greater than one standard deviation below the normative sample mean published with the test (i.e., standard scores < 85) will be classified as "poor outcome" while higher scores will be classified as "good outcome". | Approximately 18 - 20 Months | |
Secondary | Evaluation of The Impact of Melatonin using Magnetic Resonance Image (MRI) | The MRI study scores of neonates treated with hypothermia plus melatonin will be compared with historical controls that have matched Sarnat exams (exam of HIE severity at the time of admission). | Approximately 7 - 12 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02551003 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT02683915 -
Reno-protective Effect of Brain Cooling in Newborn With Hypoxia
|
||
Recruiting |
NCT01962233 -
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy
|
Phase 1 | |
Completed |
NCT01471015 -
Darbe Administration in Newborns Undergoing Cooling for Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01683383 -
California Transport Cooling Trial
|
N/A | |
Completed |
NCT01649648 -
Autologous Cord Blood Cells for Brain Injury in Term Newborns
|
Phase 1 | |
Completed |
NCT01481207 -
Magnetic Resonance Imaging and Spectroscopy Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy
|
||
Withdrawn |
NCT00993564 -
Magnetic Resonance Imaging (MRI) Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy (HIE)
|
N/A | |
Completed |
NCT00945789 -
Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)
|
Phase 1/Phase 2 | |
Completed |
NCT00097097 -
Neonatal Resuscitation in Zambia
|
Phase 3 | |
Not yet recruiting |
NCT02605018 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01128673 -
MRI Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy(HIE)
|
N/A | |
Completed |
NCT01732146 -
Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy
|
Phase 3 | |
Completed |
NCT02349672 -
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)
|
||
Completed |
NCT02826941 -
Moderate Hypothermia in Neonatal Hypoxic Ischemic Encephalopathy
|
Phase 2 | |
Active, not recruiting |
NCT01138176 -
Whole Body Cooling Using Phase Changing Material
|
Phase 1/Phase 2 | |
Recruiting |
NCT02578823 -
Targeted Temperature Management After In-Hospital Cardiac Arrest
|
N/A | |
Terminated |
NCT01765218 -
Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01241019 -
Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia
|
Phase 2 | |
Completed |
NCT00620711 -
Pilot Study of Head Cooling in Preterm Infants With Hypoxic Ischemic Encephalopathy
|
Phase 1 |